作者: Drummond, Daryl C. ; Guo, Zexiong ; Park, John W. ; Ou, Ching-Ju ; Noble, Charles O. ; Kirpotin, Dmitri B. ; Hong, Keelung ; Hayes, Mark E. ; Tseng, Yun-Long

Effective liposomal formulations of vinorelbine (5' nor-anhydro-vinblastine; VRL) have been elusive due to vinorelbine's hydrophobic structure and resulting difficulty in stabilizing the drug inside the nanocarrier. Triethylammonium salts of several polyanionic trapping agents were used initially to prepare minimally pegylated nanoliposomal vinorelbine formulations with a wide range of drug release rates. Sulfate, poly(phosphate), and sucrose octasulfate were used to stabilize vinorelbine intraliposomally while in circulation, with varying degrees of effectiveness. The release rate of vinorelbine from the liposomal carrier was affected by both the chemical nature of the trapping agent and the resulting drug-to-lipid ratio, with liposomes prepared using sucrose octasulfate displaying the longest half-life in circulation (9.4 h) and in vivo retention in the nanoparticle (t(1/2) = 27.2 h). Efficacy was considerably improved in both a human colon carcinoma (HT-29) and a murine (C-26) colon carcinoma model when vinorelbine was stably encapsulated in liposomes using triethylammonium sucrose octasulfate. Early difficulties in preparing highly pegylated formulations were later overcome by substituting a neutral distearoylglycerol anchor for the more commonly used anionic distearoylphosphatidylethanolamine anchor. The new pegylated nanoliposomal vinorelbine displayed high encapsulation efficiency and in vivo drug retention, and it was highly active against human breast and lung tumor xenografts. Acute toxicity of the drug in immunocompetent mice slightly decreased upon encapsulation in liposomes, with a maximum tolerated dose of 17.5 mg VRL/kg for free vinorelbine and 23.8 mg VRL/kg for nanoliposomal vinorelbine. Our results demonstrate that a highly active, stable, and long-circulating liposomal vinorelbine can be prepared and warrants further study in the treatment of cancer.

2008-11-01·Journal of pharmaceutical sciences3区 · 医学

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development

3区 · 医学

Review

作者: Dmitri B. Kirpotin ; John W. Park ; Daryl C. Drummond ; Charles O. Noble ; Mark E. Hayes

Liposomes represent a widely varied and malleable class of drug carriers generally characterized by the presence of one or more amphiphile bilayers enclosing an interior aqueous space. Thus, the pharmacological profile of a particular liposomal drug formulation is a function not only of the properties of the encapsulated drug, but to a significant extent of the pharmacokinetics, biodistribution, and drug release rates of the individual carrier. Various physicochemical properties of the liposomal carriers, the drug encapsulation and retention strategies utilized, and the properties of the drugs chosen for encapsulation, all play an important role in determining the effectiveness of a particular liposomal drug. These properties should be carefully tailored to the specific drug, and to the application for which the therapeutic is being designed. Liposomal carriers are also amenable to additional modifications, including the conjugation of targeting ligands or environment-sensitive triggers for increasing the bioavailability of the drug specifically at the site of disease. This review describes the rationale for selecting optimal strategies of liposomal drug formulations with respect to drug encapsulation, retention, and release, and how these strategies can be applied to maximize therapeutic benefit in vivo.

2007-10-01·Neuro-oncology1区 · 医学

Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts

1区 · 医学

Article

作者: Daryl Drummond ; Dmitri B. Kirpotin ; Erika Kullberg ; Charles O. Noble ; Michal T. Krauze ; Krystof S. Bankiewicz ; John Forsayeth ; John W. Park ; Tomohiro Kawaguchi ; Yoji Yamashita

We have previously shown that convection-enhanced delivery (CED) of highly stable nanoparticle/liposome agents encapsulating chemotherapeutic drugs is effective against intracranial rodent brain tumor xenografts. In this study, we have evaluated the combination of a newly developed nanoparticle/liposome containing the topoisomerase I inhibitor CPT-11 (nanoliposomal CPT-11 [nLs-CPT-11]), and PEGylated liposomal doxorubicin (Doxil) containing the topoisomerase II inhibitor doxorubicin. Both drugs were detectable in the CNS for more than 36 days after a single CED application. Tissue half-life was 16.7 days for nLs-CPT-11 and 10.9 days for Doxil. The combination of the two agents produced synergistic cytotoxicity in vitro. In vivo in U251MG and U87MG intracranial rodent xenograft models, CED of the combination was also more efficacious than either agent used singly. Analysis of the parameters involved in this approach indicated that tissue pharmacokinetics, tumor microanatomy, and biochemical interactions of the drugs all contributed to the therapeutic efficacy observed. These findings have implications for further clinical applications of CED-based treatment of brain tumors.

项与 Hermes Biosciences, Inc. 相关的新闻（医药）

2021-07-01

·GlobeNewswire

NewAge, Inc., Honored by Hermes Awards for Its Direct-to-Consumer and Social Media Marketing

DENVER, July 01, 2021 (GLOBE NEWSWIRE) -- NewAge, Inc. (Nasdaq: NBEV), the Colorado-based organic and healthy products company intending to become the world’s leading social selling and distribution company, today announced that NewAge, Inc. has been honored as a five-time award winner in both direct-to-consumer marketing and corporate image categories in the Hermes Creative Awards Competition. Hermes Creative Awards is an international competition for creative professionals involved in the concept, writing and design of traditional and emerging media. Hermes Creative Awards recognizes outstanding work in the industry while promoting the philanthropic nature of marketing and communication professionals. Administered by the Association of Marketing and Communication Professionals (AMCP), the international organization consists of several thousand marketing, communication, advertising, public relations, digital media production and freelance professionals. AMCP oversees awards and recognition programs, provides judges and awards for outstanding achievement and service to the profession. Judges are industry professionals who look for companies and individuals whose talent exceeds a high standard of excellence and whose work serves as a benchmark for the industry. NewAge, Inc. was awarded the highest honors for its creative social media campaign and design work in Interactive Social Media for its Icon Social Series and also won in the Interactive Media category for its NewAge Share App. In the Interactive Social Media Campaign category, New Age’s Lucim™ brand was honored for its Mother’s Day Social Series. NewAge also won awards for its Lucim Sunscreen Social Series that it launched in China earlier this year, and its Lucim Skincare Social Series. The Lucim brand continues to gain notoriety, was recently highlighted in Italian Vogue, and was also recognized by the Good Face Project as being some of the highest quality, clean, non-toxic skincare available worldwide. More than 6,000 entries were received for the Hermes Creative Awards 2021 competition, with NewAge being one of leading award recipients recognized with 5 awards. Karima McDaniel, VP of Marketing at NewAge commented, “Our direct/social selling business experienced a year-over-year sales increase of 128% last year. We continue to lead the evolution of Direct-to-Consumer (D2C) industry with leading tools, content, and technology for our more than 400,000 brand partners and customers across more than 50 countries. This achievement highlights our dedication to leading the industry and the social selling revolution by providing award-winning content for our Brand Partners and consumers. We are honored to be recognized by the Hermes Creative Awards and believe we are well on our way to achieving our vision of becoming the world’s leading social selling and distribution company.” About Hermes Creative AwardsHermes Creative Awards is administered and judged by the Association of Marketing and Communication Professionals . The AMCP have coordinated and judged the awards for more than 20 years. Entrants contend for Platinum and Gold statuettes – wings from the mythological Hermes’ cap and sandals, elegantly etched to evoke the shape of the letter H.About NewAge, Inc.NewAge is a purpose-driven firm intending to become the world’s leading social selling and distribution company. Colorado-based NewAge commercializes a portfolio of organic and healthy products worldwide through primarily a direct route-to-market system. The company competes in three major category platforms including health and wellness, inner and outer beauty, and nutritional performance and weight management — leading a network of more than 400,000 exclusive independent distributors and Brand Partners around the world. The company operates the websites NewAge.com, NoniNewAge.com, ARIIX.com, MaVie.com, TheLIMUCompany.com and Zennoa.com websites. Safe Harbor Disclosure This press release contains forward-looking statements that are made under the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management's expectations regarding future results of operations, economic performance, and financial condition. The forward-looking statements are based on the assumption that operating performance and results will continue in line with historical results. Management believes these assumptions to be reasonable, but there is no assurance they will prove to be accurate. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. NewAge competes in a rapidly growing and transforming industry, and risk factors, including those disclosed in the Company's filings with the Securities and Exchange Commission, might affect the Company's operations. Unless required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements. For investor inquiries about NewAge please contact: NewAge Investor & Public Relations:Mindy EardleyDirector, Public and Investor RelationsTel: 1-801-573-4818Mindy_Eardley@NewAge.com NewAge Investor RelationsBPC Financial Marketing800 816 7361ir@bpcfinancialmarketing.com A photo accompanying this announcement is available at

100 项与 Hermes Biosciences, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Hermes Biosciences, Inc. 相关的转化医学

登录后查看更多信息